Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by MarketMoneyon Jan 07, 2022 5:51pm
223 Views
Post# 34294880

RE:Grail only 18% Stage 1 and 43% Stage 2

RE:Grail only 18% Stage 1 and 43% Stage 2

LithLover wrote: I recently saw someone on CEO. ca talking about Grail.  I mean come on they are less than 50% detecting cancers up to Stage 2 and yet look at their market value and all the marketing and hype they get.

18% at Stage 1 and 43% for Stage 1 and 2.  Come on.

Stagezero's (detecting cancers at Stage 0) time will come.


https://www.oncodna.com/en/company/activity/news-list/cancer-screening-early-detection-a-methylation-based-ctdna-assay-from-grail-delivered-sensitivity-93-for-stage-iv-cancer-falling-to-43-for-stage-ii-and-18-for-stage-i-disease/




Again it prove's that shareprice is driven by the demand and supply of it's shares....no mater what the fundamental is saying.

Look at Gamestop market valuation and what the fundamental is worthed....an insane market cap because of demand for that stock during short squeeze made them a high evaluation market cap. 

One day SZLS will do the same, once's investors will want shares of SZLS in their portofolio and the supply wouldn't be able to sustain the demand, shareprice will increase. 

And one last thing, you will notice basher will use the shareprice as an indicator of how a company is doing....which is a non-sense as shareprice and day to day bussiness is 2 different things. They both have demand and supply market but one is about shares and the other is about products/services. 

At the end, is theses test saves life, the company have succeeded on their mission. After that, the rest will follow...

have a great weekend!


 

<< Previous
Bullboard Posts
Next >>